The latest data shows EXAS generated revenue of $713M in Q4 2024, up 17% year-over-year. This revenue growth acceleration is a positive signal, as EXAS revenue grew just 8% year-over-year in the prior quarter. The uptick in revenue growth indicates that EXAS's core genetic testing business is gaining momentum, as more patients adopt its outpatient-focused diagnostic services. This aligns with the company's strategy to expand access to its tests through partnerships with healthcare providers. Profitability has also improved, with EXAS reporting a net loss of $86M in Q4 2024 compared to a $207M loss in the prior-year period. This demonstrates EXAS's ability to drive operating leverage as it scales its business. The combination of accelerating revenue growth and margin improvement signals that EXAS is executing effectively on its strategy to expand outpatient genetic testing adoption. As the company continues to sign up new healthcare provider partners, I expect this positive momentum to continue. Looking ahead, I believe EXAS is positioned for further upside. The company's Q: data shows it has grown revenue at a 20% compound annual rate over the past 2 years, while narrowing its net loss. I expect this favorable trend to persist, driving the stock higher over the next 6-12 months.

Research these companies